Key result
Hematopoietic Kdm3a deficiency attenuates atherosclerosis and plaque necrosis by suppressing macrophage interferon signaling.
Why the study?
Macrophages drive atherosclerosis through inflammatory activation programs shaped by epigenetic reprogramming, and the role of KDM3A-mediated H3K9 demethylation in regulating interferon signaling and plaque inflammation was investigated.
Does hematopoietic deficiency or inhibition of the H3K9 demethylase KDM3A attenuate macrophage interferon-driven inflammation and reduce atherosclerotic plaque progression and vulnerability?
Does hematopoietic deficiency or inhibition of the H3K9 demethylase KDM3A attenuate macrophage interferon-driven inflammation and reduce atherosclerotic plaque progression and vulnerability?
Answers are grounded in this paper and cite their sources.
Identifies the histone H3K9 demethylase KDM3A as an epigenetic driver of type I interferon-mediated macrophage inflammation and plaque instability, nominating it as a potential therapeutic target in atherosclerosis.
Macrophages drive atherosclerosis through inflammatory activation programs shaped by metabolic and epigenetic reprogramming. H3K9 methylation enforces heterochromatin states and represses transcription, whereas removal of this histone modification creates transcriptionally permissive chromatin. Here, we identified KDM3A-mediated H3K9 demethylation to enhance chromatin accessibility at interferon (IFN) signaling loci, thereby promoting IFN production and downstream IFN-dependent transcriptional and chemokine responses. In a mouse model of atherosclerosis, hematopoietic Kdm3a deficiency reduces lesion size, necrotic core formation, and neutrophil recruitment. Mechanistically, Kdm3a -deficient macrophages show impaired chemokine secretion and reduced neutrophil recruitment both in vitro and in vivo. In primary human macrophages, KDM3A knockdown suppressed IFN responses; consistently KDM3A-dependent gene signatures were enriched in IFN-inducible macrophages within human atherosclerotic plaques, and computational modeling predicted a shift toward more stable plaque phenotypes upon KDM3A inhibition. Together, these findings establish KDM3A as an epigenetic regulator that sustains IFN-driven macrophage activation and promotes progression of atherosclerosis, nominating KDM3A as a potential target for selectively modulating IFN-dependent inflammation.
No takes yet. Share an insight, caveat, or question.
Siebeler et al. (2026) studied Atherosclerosis (n=40). Hematopoietic Kdm3a deficiency (Kdm3a-/- bone marrow transplantation) and in vitro KDM3A knockdown/knockout vs. Wild-type bone marrow transplantation or scrambled LNA control was evaluated on Atherosclerotic lesion size, necrotic core formation, and plaque neutrophil recruitment in mice; correlation of KDM3A knockdown gene signature with human plaque vulnerability index (p=<0.05). Hematopoietic Kdm3a deficiency reduced atherosclerotic lesion size, necrosis, and neutrophil recruitment in Ldlr-/- mice by suppressing macrophage type I interferon signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: